Meeting
2022 ASCO Annual Meeting
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.
Authors
Arvind Dasari
The University of Texas MD Anderson Cancer Center, Houston, TX
Arvind Dasari , Yan Lin , Scott Kopetz , Samuel A. Jacobs , Peter C. Lucas , Ibrahim Halil Sahin , Dustin A. Deming , Philip Agop Philip , Theodore S. Hong , Yesenia Rojas-Khalil , Norman Wolmark , Greg Yothers , Thomas J. George , Christopher Hanyoung Lieu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer - Neo-Adjuvant/Adjuvant
Clinical Trial Registration Number
NCT05174169
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3643)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3643
Abstract #
TPS3643
Poster Bd #
429b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
First Author: Christopher Hanyoung Lieu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).
First Author: Arvind Dasari
Poster
2024 ASCO Gastrointestinal Cancers Symposium
NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-NORTH AMERICA).
First Author: Christopher Hanyoung Lieu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Ensemble study: A multicenter, randomized, phase III trial to test the superiority of consolidation irinotecan, capecitabine and oxaliplatin vs capecitabine and oxaliplatin following short course radiotherapy as total neoadjuvant therapy in patients with locally advanced rectal cancer.
First Author: Jun Watanabe